



findings contained in Section III.B. below, which are admitted, Respondent consents to the entry of this Order Instituting Administrative Proceedings Pursuant to Rule 102(e) of the Commission's Rules of Practice, Making Findings, and Imposing Remedial Sanctions ("Order"), as set forth below.

### III.

On the basis of this Order and Respondent's Offer, the Commission finds that:

A. Maza, age 69, resides in Fort Lee, New Jersey. Maza is a member of the New York State Bar and is also a certified public accountant licensed to practice in New York. Maza is not currently associated with any registered broker-dealer or investment adviser. From 2011 to 2013, Maza was the Chief Executive Officer and Chief Financial Officer of BioZone Pharmaceuticals, Inc. ("BioZone"), a publicly traded company.

B. On September 7, 2018, the Commission filed a complaint against Maza in SEC v. Honig, et al., 18-cv-8175, in the United States District Court for the Southern District of New York. On April 25, 2025, a Final Judgment was entered against Maza, permanently enjoining him, by consent, from future violations of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder. The Final Judgment also permanently enjoined Maza from aiding and abetting violations of Section 15(d) of the Exchange Act and Rule 15d-1 thereunder.

C. The Commission's complaint alleged, among other things, that, while CEO and CFO of BioZone, Maza knowingly signed the company's annual filing for fiscal year 2012, and an amended annual filing for that year, both filed with the SEC, without disclosing that certain individuals had control of more than five percent of BioZone's outstanding shares, and without disclosing that certain individuals controlled the management of the company. The complaint also alleged that Maza knowingly provided false assurance to a broker that one of these individuals had no agreement or understanding with BioZone that would preclude that individual from selling BioZone stock. Over the course of his tenure, Maza received millions of shares of BioZone stock, in addition to his salary.

#### **IV.**

In view of the foregoing, the Commission deems it appropriate and in the public interest to impose the sanction agreed to in Respondent Maza's Offer.

Accordingly, it is hereby ORDERED pursuant to Rule 102(e)(3)(i) of the Commission's Rules of Practice, effective immediately, that:

A. Maza is suspended from appearing or practicing before the Commission as an attorney.

B. Maza is suspended from appearing or practicing before the Commission as an accountant.

By the Commission.

Vanessa A. Countryman  
Secretary